about
Pharmacogenetics of healthy volunteers in Puerto RicoProgress in pharmacogenetics: consortiums and new strategiesClinical implementation of pharmacogeneticsPharmacogenetics and pharmacogenomics as tools in cancer therapyHuman genetics: international projects and personalized medicineVancomycin-induced thrombocytopenia in a newborn.Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathyPharmacogenetics of drug-metabolizing enzymes in US Hispanics.Chloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans.Clinical drug-drug interactions: focus on venlafaxine.Genomic biomarkers related to drug response in Venezuelan populations.Pharmacogenetics in Central American healthy volunteers: interethnic variability.Pharmacogenetics of drug-metabolizing enzymes in Italian populations.Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations.Clinical prospects of IGF-signaling system components study in ovarian cancer patients.Clinical pharmacy service practice in a Chinese tertiary hospital.CYP2D6 in Amerindians from Southern Mexico: low variability and higher frequency of functional alleles.Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients.Investigating the impact of missense mutations in hCES1 by in silico structure-based approaches.Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene.Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen.SLC22A2 - mapping genomic variations within South African indigenous and admixed populations.Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.Pharmacogenomics in pain treatment.The integration and interpretation of pharmacogenomics - a comparative study between the United States of America and Europe: towards better health care.Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival, and other clinical outcomes in renal transplant.Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population.Fluvoxamine-associated oscillopsia and a role for personalized medication dosing.Pharmacogenetic studies: a tool to improve antidepressant therapy.CYP2D6 variability in populations from Venezuela.An update on HLA alleles associated with adverse drug reactions.Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction.Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?Polymorphisms of CYP1A2 and CYP2A6 activity: phenotypes and the effect of age and sex in a Nigerian population.Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe.Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.Effect of rifampicin pretreatment on the oral bioavailability of domperidone in healthy human volunteers.Cytotoxicity and cytochrome P450 inhibitory activities of Clinacanthus nutans.
P1433
Q26779038-8BCF659C-91AA-4042-9EB0-A4F5EF270B1CQ28071652-E40F7BF7-F122-4CF3-B023-26C9A410F99CQ28072159-ED98A877-ECBC-40B2-B809-35316DF7A492Q28076200-5B0F7F65-51B5-435D-B313-69626CD6ABC6Q28080820-BC12DF35-0629-4843-BF60-6969DFCB2B5BQ33436804-C6C5F0B3-9A41-4FF1-A6D5-AB0A99DC20C8Q33704116-9660D64A-6E20-49DA-8147-3AD2F95D3931Q35661209-22139866-EC23-4EE9-BF56-5FC232715502Q35684236-7A5DD728-AA1D-4007-8CE3-28590E595108Q38223167-F2AB9065-661E-4675-98D4-E25D3717E244Q38254015-4D03B9EE-C817-4F41-BEF4-F0C4AC5B9490Q38285720-D451CD9D-FB64-4BBD-8427-9C9EAC0E3BA7Q38295313-DB54241B-EDA9-4321-B60E-EB19BEFAEC54Q38365410-68634633-7775-47AB-97A1-1ABE2F554410Q38388873-96DB6D6D-1E6E-449A-AE93-0C4F46FF8241Q38459555-7FD8EEC3-C647-4FC3-BEE7-40D278C39849Q38604859-6EE0B9B3-4049-4444-8415-79897EAFCCCEQ38610763-7F837C55-A435-4751-ABA5-176FB34F3349Q38634778-72EDE259-2532-4201-BBE3-261778FE8CB9Q38681753-87E976EF-7D62-4E90-A7CC-70B3FEB9406BQ38743518-259087A4-8B28-43D1-A0D6-1BB79D575C47Q38750677-559F9907-22D5-433E-BC12-30AF7A5BC737Q38773706-6A45AF2D-AF0A-4090-85BE-CDA7448F6F9CQ38797064-136F66CF-9B20-4E61-9438-85987C1EDFECQ38802517-FBD92B04-1182-4DBA-B625-F37AA6128A49Q38818279-52CC4F41-250C-404C-9709-F0E793A71DC0Q38857409-C3C96DE5-958D-4D14-A61D-95E92CEFDF67Q38937341-6B2E2F1F-E23F-46E9-94FA-34764D315C6AQ38946020-0862C412-7A56-4CB5-BC8B-DB1476A8EBFEQ38965911-FB8EB097-6C70-4866-A12F-E22A53C94D0FQ39021032-D2FE3F20-A685-4699-ABB9-62F1D7262BD1Q39163557-4F55B768-6157-4DC8-A743-0178B9BE48C2Q39186078-3D1F956E-6DE8-4016-837F-F25670A5987FQ39309971-9B88E904-353C-443D-8AC1-7D50DEA9F082Q39543114-E80DF306-4E49-44E4-9E9F-1A3244FAA37CQ40812008-0FD633A6-B8D4-49CA-8D29-56232EC8F0AFQ40877276-3DB3C39E-02F7-4E77-BDF9-AFD9029C9642Q40916355-09421C14-5ADE-436E-98A2-175335FD7ED1Q41008408-CB30D600-F8A6-4680-8D84-305B01A48C24Q42802393-79A0E6C6-8233-4ED5-810C-35ECD9970BDD
P1433
description
journal
@en
revista científica
@es
wetenschappelijk tijdschrift van Walter de Gruyter
@nl
wissenschaftliche Fachzeitschrift
@de
name
Drug metabolism and personalized therapy
@ast
Drug metabolism and personalized therapy
@en
Drug metabolism and personalized therapy
@es
Drug metabolism and personalized therapy
@nl
type
label
Drug metabolism and personalized therapy
@ast
Drug metabolism and personalized therapy
@en
Drug metabolism and personalized therapy
@es
Drug metabolism and personalized therapy
@nl
altLabel
Drug Metab Pers Ther
@en
prefLabel
Drug metabolism and personalized therapy
@ast
Drug metabolism and personalized therapy
@en
Drug metabolism and personalized therapy
@es
Drug metabolism and personalized therapy
@nl
P1055
P1156
21100389517
P1250
P1277
P1476
Drug metabolism and personalized therapy
@en